# a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

> **NCT04781634** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 40 (estimated)

## Conditions studied

- B-ALL

## Interventions

- **BIOLOGICAL:** CD19 and CD22 targeted prime CAR-T cells

## Key facts

- **NCT ID:** NCT04781634
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-07
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-07-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04781634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04781634, "a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04781634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*